Navigation Links
5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded
Date:3/16/2010

(March 16, 2010--Bethesda, MD.) The National Foundation for Cancer Research announced today that renowned scientist Peter K. Vogt, Ph.D., Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute, La Jolla, California, is the recipient of the 5th Annual Szent-Gyrgyi Prize for Progress in Cancer Research.

Dr. Vogt's research, which began on a humble chicken virus in the early 1960s, has profoundly changed biology and medicine. His groundbreaking discovery of src, the first cancer-causing gene, or oncogene, launched a new era for cancer research and made seminal contributions to our present understanding of the role of oncogenes, proto-oncogenes and many other critical molecular mechanisms of cancer. Today, Dr. Vogt continues to be a leader in multiple aspects of cancer research, including initiatives that use some of the most important oncogenes as therapeutic targets initiatives that are bringing renewed hope to cancer patients.

"Dr. Vogt's fundamental basic science discovery of cancer-causing genes in retroviruses shed the first light on the genetic paradigm that now dominates our understanding of cancer development in humans," said Ronald A. DePinho, M.D., Chair of the Szent-Gyrgyi Prize Selection Committee and last year's recipient. "His groundbreaking work has yielded several of the most important targets in cancer therapy. We are honored to present this coveted award to an individual of iconic stature. "

"The significance of Dr. Vogt's remarkable research cannot be overstated. The impact of his discoveries on our understanding of tumor formation is immense," said Sujuan Ba, Ph.D., Co-Chair of the 5th Annual Szent-Gyrgyi Prize Selection Committee and Chief Operating Officer of NFCR. "We are quite pleased to honor him and celebrate his role in advancing cancer research."

Named in memory of 1937 Nobel Prize-winning scientist and NFCR Co-Founder Albert Szent-Gyrgyi, the Prize is awarded annually to a scientist, nominated by colleagues or peers, who has contributed outstanding, substantial research to the fight against cancer and whose accomplishments have helped improve treatment options for cancer patients. The Prize includes a $25,000 cash award and will be presented to Dr. Vogt on March 16, 2010 at the Hilton New York at an award ceremony featuring a keynote address by John Lechleiter, Ph.D., Chairman, President, and Chief Executive Officer, Eli Lilly and Company.

"I am immensely grateful and delighted to be awarded the 2010 Albert Szent-Gyrgyi Prize for Progress in Cancer Research," said Dr. Vogt. "This award marks a milestone in my scientific career and gives me both encouragement and inspiration. Albert Szent-Gyrgyi's consuming interest during the last two decades of his life was cancer. Being a fiercely independent man, he chose an unusual path to support his research: the establishment of a private foundation. By the power of his personality and his scientific stature, he succeeded in creating the National Foundation for Cancer Research. For almost 40 years, the unique focus of NFCR on research has provided critical support to innovative scientists and has advanced the translation of basic knowledge into successful therapy."

Dr. Peter Vogt's revolutionary research on src has led to the discovery of additional oncogenes, including myc, jun, and PI 3-kinase, that play a key role in human cancer and have become household names in the world of cellular signaling research. His current work on cancer-specific mutations in p110, the catalytic subunit of PI 3-kinase, has demonstrated that these mutations confer oncogenic activity on the protein, making them highly specific cancer targets. Pursuing these targets, Dr. Vogt is now generating small molecule inhibitors that can interfere with their role in cancer causation. Dr. Vogt's iconic career may have begun with oncogene discovery but it has expanded in scope and now includes translational studies aimed at developing novel therapeutic approaches for cancer patients.

Currently, Dr. Vogt is a Professor in the Department of Molecular and Experimental Medicine at The Scripps Research Institute in La Jolla, California. He has received many awards and honors, including the Gregor Johann Mendel Medal, Charles S. Mott Prize, Ernst Jung Prize for Medicine, Bristol Meyers Award, and ICN International Prize in Virology. Dr. Vogt has been invited as a distinguished lecturer by more than twenty leading research institutions in the US, Europe, and Asia, among them the German Cancer Research Center in Heidelberg for the Meyenburg Foundation Lecture, the Princess Takamatsu Foundation, the Alexander von Humboldt Foundation of the Federal Republic of Germany and the Agency for Science, Technology and Research of Singapore. He was also elected an Honorary Member of the Japanese Cancer Association and received an honorary doctorate from the University of Wrzburg. Dr. Vogt is an elected member of many prestigious academies, including the American Academy of Arts and Sciences, the National Academy of Sciences, the Institute of Medicine of the National Academies, and the American Academy of Microbiology. He received his Ph.D. from the University of Tbingen, Germany, and trained as a virologist at the Max Planck Institute of Virology in Germany and at the University of California in Berkeley.


'/>"/>

Contact: Silas Deane
sdeane@nfcr.org
615-319-6007
National Foundation for Cancer Research
Source:Eurekalert

Related biology news :

1. University of Chicago and Ataxia Foundation team up for annual scientific and patient meetings
2. P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting
3. Society of Interventional Radiology hosts 35th Annual Scientific Meeting
4. Press registration open for Society of Interventional Radiology’s 35th Annual Scientific Meeting
5. SCM Microsystems Announces Results of Annual Meeting
6. 2009 Annual Meetings emphasize sustainability
7. TGen provides Arizona with $77 million in annual economic impact
8. Quality of medicines and food ingredients the focus at USP 2009 Annual Scientific Meeting
9. Annual survey shows high numbers of seed scallops on Georges Bank, low numbers in Mid-Atlantic
10. Science communication to take the stage at annual AAAS meeting in San Francisco
11. Symposium to discuss geoengineering to fight climate change at the ESA Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... Va. , Feb. 2, 2016   ... award from the U.S. Army Research Office and ... the range and sensitivity of the company,s ... Past Accounting Mission and, more generally, defense-related DNA ... DNA phenotyping capabilities (predicting appearance and ancestry from ...
(Date:2/1/2016)... Rising sales of consumer electronics ... intuitive gesture control market size ... consumer electronics coupled with new technological advancements to drive ... through 2020   --> ... advancements to drive global touchfree intuitive gesture control market ...
(Date:2/1/2016)... , Feb. 1, 2016  Wocket® smart wallet ( www.wocketwallet.com ) ... television personality, Joey Fatone . Las Vegas ... fans. --> Las Vegas , where Joey ... --> The new video ad was filmed at the Consumer Electronics ... at the Wocket booth to meet and greet fans. ...
Breaking Biology News(10 mins):
(Date:2/11/2016)... ... February 11, 2016 , ... Global Stem ... clinic in Quito, Ecuador. The new facility will provide advanced protocols and state-of-the-art ... around the world. , The new GSCG clinic is headed by four ...
(Date:2/10/2016)... -- The Maryland House of Delegates and House Speaker ... Maryland School of Medicine Dean E. Albert Reece ... System President and CEO Robert Chrencik , MBA, ... given to the public by the leader of the ... and Mr. Chrencik for their contributions to our statewide ...
(Date:2/10/2016)... New York, New York (PRWEB) , ... ... ... Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) today announced that it has joined the ... vaccines and immunotherapies for infectious diseases and cancer. , The Human ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., ... for fast growing biotech companies, announced today the ... Procurement Strategic Advisor. Jim brings nearly 25 years ... and procurement, having spent nearly two decades in ... Chain/Logistics and Procurement at Genzyme and, most recently ...
Breaking Biology Technology: